Lepu Medical(SZ:300003) Bei Jing Shang Bao·2025-04-20 12:51Core Viewpoint - Lepu Medical has experienced a significant decline in performance, with net profit plummeting over 80% in 2024, marking the worst performance since its listing in 2009 [1][3][6]. Financial Performance - In 2024, the company reported operating revenue of approximately 6.1 billion yuan, a decrease of 23.52% year-on-year [2][3]. - The net profit attributable to shareholders was about 246.94 million yuan, down 80.37% compared to the previous year [2][3]. - The net profit after deducting non-recurring gains and losses was approximately 221.43 million yuan, reflecting an 80.28% decline [2][3]. - The net cash flow from operating activities was 734.64 million yuan, a decrease of 25.82% [2]. - Basic and diluted earnings per share were both 0.1336 yuan, down 80.23% [2]. - The total assets at the end of 2024 were approximately 24.57 billion yuan, a decrease of 1.80% from the previous year [2]. Business Segments - The medical device segment, the largest revenue contributor, generated 3.33 billion yuan, down 9.47% year-on-year [9]. - The pharmaceutical segment reported revenue of 1.76 billion yuan, a decline of 42.25%, with the generic drug revenue dropping 46.5% [9][10]. - The medical services and health management segment achieved revenue of 1.02 billion yuan, down 19.24% [11]. Asset Impairment - The company recorded impairment losses on goodwill and other specific assets totaling approximately 251 million yuan, impacting net profit by about 217 million yuan [6][8]. - High inventory impairment provisions were noted, with a total of about 168 million yuan, including 136 million yuan for testing products [7]. Strategic Adjustments - The company is dynamically adjusting its business strategies across segments to promote sustainable high-quality development [11]. - There is a strategic shift towards innovative drugs and skin injection products, while reducing investment in generic drugs [10][11].